GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder associated with many comorbidities, including obesity, diabetes, cardiovascular risk factors, mental health issues, and many more disorders. Current treatments including biologics, topicals, and surgical interventions often fall short in terms of patient satisfaction, demonstrating a need for additional innovative approaches that address HS-related comorbidities.
This review explores the novel application of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in HS treatment, particularly for patients with comorbid conditions such as metabolic syndrome, diabetes, and obesity. Emphasis is placed on combination therapy and the potential for GLP-1RAs to address both HS symptoms and associated comorbidities, with careful consideration of patient selection.
A review of emerging evidence and existing literature on GLP-1RAs and their applications for weight loss, metabolic regulation, and anti-inflammatory effects was conducted.
GLP-1RAs offer dual benefits for HS patients by modulating inflammatory pathways and addressing associated comorbid conditions. Case studies and preliminary data suggest that GLP-1RAs may reduce lesion severity, systemic inflammation, and morbidity, either as monotherapy or in conjunction with existing treatments. However, high-quality randomized controlled trials are indicated to confirm these findings.
GLP-1RAs represent a promising adjunctive or standalone treatment choice for those with HS and its related comorbidities. Further research is needed to establish their safety and efficacy in HS treatment.  .
This review explores the novel application of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in HS treatment, particularly for patients with comorbid conditions such as metabolic syndrome, diabetes, and obesity. Emphasis is placed on combination therapy and the potential for GLP-1RAs to address both HS symptoms and associated comorbidities, with careful consideration of patient selection.
A review of emerging evidence and existing literature on GLP-1RAs and their applications for weight loss, metabolic regulation, and anti-inflammatory effects was conducted.
GLP-1RAs offer dual benefits for HS patients by modulating inflammatory pathways and addressing associated comorbid conditions. Case studies and preliminary data suggest that GLP-1RAs may reduce lesion severity, systemic inflammation, and morbidity, either as monotherapy or in conjunction with existing treatments. However, high-quality randomized controlled trials are indicated to confirm these findings.
GLP-1RAs represent a promising adjunctive or standalone treatment choice for those with HS and its related comorbidities. Further research is needed to establish their safety and efficacy in HS treatment.  .